Research
Hormonal
A ketogenic diet (KD) improves insulin sensitivity and reduces insulin requirements in patients with type 2 diabetes and obesity by lowering glycemic response and reducing pancreatic insulin secretion.
To improve insulin sensitivity, restrict carbohydrates to under 50g per day while maintaining high fat intake (approx 75% of calories) and moderate protein (1-1.4g/kg). Expect initial side effects like fatigue or 'keto flu' due to electrolyte shifts, which typically resolve as your body adapts.
ModerateSupportsMEDIUM confidence
KD has been shown to control blood glucose, decrease the need for insulin release [39], and improve IR by lowering the glycemic response generated by CHO in studies done on adult diabetic patients and in obese children and adolescents [41,42].
Why this rating
The paper is a review citing multiple human and animal studies, but does not present new primary data with specific statistical effect sizes for this specific claim.
Source
Low-Carbohydrate High-Fat Diet: A SWOC Analysis
Dena A. Nuwaylati et al. · Metabolites · 2022
DOI 10.3390/metabo12111126
narrative_reviewCited 34×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Long-term adherence to a ketogenic diet carries risks of nutritional deficiencies, electrolyte disturbances, and potential renal stones (nephrolithiasis), requiring strict monitoring.Good
- A ketogenic diet reduces oxidative stress and improves mitochondrial function by activating antioxidant pathways (Nrf2) and scavenging reactive oxygen species (ROS) via ketone bodies like beta-hydroxybutyrate.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →